@article{c947ed4a6f104bd8bbd560ae765de147,
title = "Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab",
abstract = "Patients with ataxia telangiectasia (AT) with malignancies face poor prognosis due to increased treatment-related toxicity. Here, we report a 14-year-old male with AT and Hodgkin lymphoma (HL) who received brentuximab vedotin and reduced COPP plus rituximab courses. This treatment resulted in complete remission and showed no severe toxicity.",
keywords = "Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Ataxia Telangiectasia/complications, Brentuximab Vedotin, Cyclophosphamide/administration & dosage, Epstein-Barr Virus Infections/complications, Herpesvirus 4, Human, Hodgkin Disease/complications, Humans, Immunoconjugates/administration & dosage, Male, Prednisone/administration & dosage, Procarbazine/administration & dosage, Remission Induction, Rituximab/administration & dosage, Vincristine/administration & dosage, Young Adult",
author = "Meister, {Michael T} and Sandra Voss and Dirk Schwabe",
note = "{\textcopyright} 2015 Wiley Periodicals, Inc.",
year = "2015",
month = nov,
doi = "10.1002/pbc.25621",
language = "English",
volume = "62",
pages = "2018--20",
journal = "Pediatric blood & cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "11",
}